Preclinical Alzheimer Disease Is Not Significantly Affected by Solanezumab.

Published Date: 19 Oct 2023

Based on the primary or secondary cognitive and functional end points over a 4–5 year treatment period, solanezumab did not slow the progression of preclinical Alzheimer disease in comparison to placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot